

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
	Applicant Brian Smith, et al.		
	Filing Date May 26, 2006	Group Art Unit	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	US 3652543	3/28/72	Hoegerle			
	A2	US 3716639	2/13/73	Hoegerle et al.			
	A3	US 3795683	3/05/74	Brossi et al.			
	A4	US 4108989	8/22/78	Holden			
	A5	US 4111957	9/05/78	Holden et al.			
	A6	US 4210749	7/01/80	Shetty			
	A7	US 4210729	7/01/80	Bola V. Shetty			
	A8	US 4233217	11/11/80	Shetty			
	A9	US 5387685	2/07/85	Powell et al.			
	A10	US 4762845	8/09/88	Chu et al.			
	A11	US 4988690	1/29/91	Effland et al.			
	A12	US 5015639	5/14/91	Berger et al.			
	A13	US 5178786	1/12/93	Jahnke et al.			
	A14	US 5387685	7/16/93	Powell et al.			
	A15	US 5275915	1/04/94	Kojima et al.			
	A16	US 5412119	5/02/95	Brussee et al.			
	A17	US 5422355	6/06/95	White et al.			
	A18	US 5691362	11/25/97	McCormick et al.			
	A19	US 5750520	5/12/98	Danilewicz et al.			
	A20	US 5856503	1/05/99	Aebi et al.			
	A21	US 5861393	1/19/99	Danilewicz et al.			
	A22	US 5925651	7/20/99	Hutchinson			
	A23	US 5939415	8/17/99	Laufer et al.			
	A24	US 5942535	8/24/99	Laufer et al.			
	A25	US 5958943	9/28/99	Laufer et al.			
	A26	US 6087346	7/11/00	Glennon et al.			
	A27	US 6218385	4/17/01	Adam et al.			

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
	Applicant Brian Smith, et al.		
	Filing Date May 26, 2006	Group Art Unit	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A28	US 6218385	4/17/01	Geo Adam et al.			
	A29	US 6900313	5/31/05	Wasserscheid et al.			
	A30	US 6953787	10/11/05	Smith et al.			
	A31	US 6972295	12/06/05	Hagmann et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	A32	DE 1944121	3/19/70	Germany				
	A33	CH 500194	1/29/71	Switzerland				
	A34	GB 1221324	2/03/71	United Kingdom				
	A35	GB 1225053	3/17/71	United Kingdom				
	A36	GB 1268243	3/22/72	United Kingdom				
	A37	NL 7807819	7/21/78	Netherlands				
	A38	EP 0007070	1/23/80	Europe				
	A39	CA 1090797	12/02/80	Canada				
	A40	GB 1599705	10/07/81	United Kingdom				
	A41	EP 0080779 A1	6/08/83	Europe				
	A42	DE 3315106 A1	11/03/83	Germany				
	A43	EP 0096838 A1	12/28/83	Europe				
	A44	EP 0161350 A1	11/21/85	Europe				
	A45	EP 0174118 A2	3/12/86	Europe				
	A46	EP 0285287 A3	3/23/87	Europe				
	A47	EP 0285919	10/12/1988	Europe				
	A48	WO 8807858	10/20/88	WIPO				
	A49	WO 9119698	12/26/91	WIPO				
	A50	WO 9300094	1/07/93	WIPO				
	A51	JP 5339263	12/21/93	Japan				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	A52	JP 06298746	10/25/94	Japan				
	A53	WO 9513274	5/18/95	WIPO				
	A54	CA 2197789	8/16/95	Canada				
	A55	WO 9604271	2/15/96	WIPO				
	A56	WO 9605194	2/22/96	WIPO				
	A57	JP 08134048	5/28/96	Japan				
	A58	WO 9633993	10/31/96	WIPO				
	A59	JP 09030960	2/04/97	Japan				
	A60	JP 90987258	3/31/97	Japan				
	A61	WO 97/24364	7/10/97	WIPO				
	A62	WO 9806701	2/19/98	WIPO				
	A63	WO 9840385	9/17/98	WIPO				
	A64	WO 99/24411	5/20/99	WIPO				
	A65	EP 0987235 A1	3/22/00	Europe				
	A66	EP 1074549 A2	2/07/01	Europe				
	A67	WO 0240471	5/23/02	WIPO				
	A68	WO 0248124	6/20/02	WIPO				
	A69	WO 02074746	9/26/02	WIPO				
	A70	WO 03000663	1/03/03	WIPO				
	A71	WO 2003/027068	4/03/03	WIPO				
	A72	WO 2003/062392	7/31/03	WIPO				
	A73	WO 03086306	10/23/03	WIPO				
	A74	EP 987235	12/03/03	Europe				
	A75	WO 04037788	5/06/04	WIPO				
	A76	WO2005/019179A2	03/03/2005	PCT				
	A77	WO2005/042490A1	05/12/2005	PCT				
	A78	WO2005/042491A1	05/12/2005	PCT				

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
	Applicant Brian Smith, et al.		
	Filing Date May 26, 2006	Group Art Unit	

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	A79	WO 2006/013209	2/09/06	WIPO				
	A80	WO 2006/043710	4/27/06	WIPO				
	A81	WO2006/069363A2	06/29/06	WIPO				
	A82	WO2006/071740A2	07/06/06	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	A83	Barnes, T. R., "Pharmacological Strategies for Relapse Prevention in Schizophrenia", <i>Psychiatry</i> 3(10): 37-40 (2004)
	A84	Chahal et al., IDdb Meeting Report 2000, May 17-18
	A85	Chang et al., "Dopamine receptor binding properties of some 2, 3, 4, 5-tetrahydro-1H-3-benzazapine-7-ols with non-aromatic substituents in the 5-position", <i>Bioorg. Med. Chem. Lett.</i> 2:399-402 (1992)
	A86	Deady et al., "Synthesis of some tetrahydro-2-and 3-benzazepines, and of hexahydro-3-benzazocine", <i>Journal of the Chemical Society, Perkins Transactions</i> 1, 1973 pp. 782-783
	A87	Di Chiara G., (2002) <i>Behavioural Brain Research</i> , 137: 75-114
	A88	Di Chiara et al., "Reward System and Addiction: What Dopamine Does and Doesn't Do", <i>Current Opinion in Pharmacology</i> 7:69-76 (2007)
	A89	Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision, Washington, DC, American Psychiatric Association, 2000*
	A90	Di Matteo et al., "Role of 5-HT _{2C} Receptors in the Control of Central Dopamine Function", <i>Trends in Pharmacological Sciences</i> 22(5):229-232 (2001)
	A91	Flannery-Schroeder, E. C., "Reducing Anxiety to Prevent Depression", <i>Am. J. Prev. Med.</i> 31(6S1):S136-S142 (2006)
	A92	Fuchs et al., "Total synthesis of (+/-)-lennoxamine and (+/-)-aphanorphine by intramolecular electrophilic aromatic substitution reactions of 2-amidoacroleins", <i>Organic Letters</i> , 2001, pp. 3923-3925, 3(24) American Chemical Society
	A93	Gallant et al., (1967) <i>Current Therapy Research</i> 9(11):579-81
	A94	Gardent et al., "Sur quelques de l' amino-2-bromo-4 1H benzazepine-3 et de ses derives", <i>Bull Soc. Chim. France</i> 2:600-605 (1968)
	A95	Gerace et al., "Predictors of Weight Increases over 7 Years in Fire Fighters and Paramedics", <i>Preventive Medicine</i> 94:593-600 (1996)
	A96	Gobert et al., (2000) <i>Synapse</i> 36: 205-221
	A97	Gombar et al., "Pharmacokinetics of a series of 6-chloro-2, 3, 4, 5-tetrahydro-3-substituted-1H-3-benzazepines in rats", <i>Drug Metab. Disposition</i> 16:367-372 (1988)
	A98	Greene et al., <i>Protective Groups in Organic Syntheses</i> , 2 nd Ed., Wiley and Sons, NY (1991)*

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A99	Halford et al., "Serotonergic Drugs: Effects on Appetite Expression and Use for the Treatment of Obesity", <i>Drugs</i> 67(1):27-55 (2007)
	A100	Halford, J.C.G., "Obesity Drugs in Clinical Development", <i>Current Opinion in Investigational Drugs</i> 7(4):312-318 (2006)
	A101	Hassine-Coniac et al., "Preparation et proprietes d'aldehydes dans la serie de la benzazapine-3", <i>Bull Soc. Chim. France</i> 11:3985-3992 (1971)
	A102	Hazebroucq, "Acces a des I-H, tetrahydro-2, 3, 4, 5 benzazepines-3 one-1 et a des hexahydro imidazo isoquinoleines", <i>Ann. Chim.</i> (1966) pp. 221-254
	A103	Hester et al., (1968) <i>J. Med. Chem.</i> 11(1): 101
	A104	Higgins et al., (2003) <i>European Journal of Pharmacology</i> , 480: 151
	A105	Hitzig, P., (1994) <i>Journal of Substance Abuse Treatment</i> , 11(5): 489
	A106	Im et al., (2003) <i>Molecular Pharmacology</i> , 64: 78-84
	A107	Jandacek, R.J., "APD-356 (Arena)", <i>Current Opinion in Investigational Drugs</i> 6(10):1051-1056 (2005)
	A108	Jenck et al., (1998) <i>European Neuropsychopharmacology</i> 8: 161 (Abstract)
	A109	Jensen et al., "Potential Role of New Therapies in Modifying Cardiovascular Risk in Overweight Patients with Metabolic Risk Facts", <i>Obesity</i> 14 (Suppl. 3):143S-149S (2006)
	A110	Karasu et al., (2000) Practice Guideline for the Treatment of Patients with Major Depressive Disorder
	A111	Koplan et al., "Preventing Childhood Obesity: Health in the Balance, Executive Summary", http://www.nap.edu/catalog/11015.html , 41 pages (2005)
	A112	Krull, O. and Wunch, B., "Synthesis and Structure/NMDA Receptor Affinity Relationships of 1-Substituted Tetrahydro-3-benzazepines", <i>Bioorganic and Medicinal Chemistry</i> , 12, pp. 1439-1451, 2004.
	A113	Ladd et al., "Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 2-benzazepines, and 9-(Aminomethyl) fluorenes", <i>J. Med. Chem.</i> , Vol. 29:1904-1912 (1986)
	A114	Lam RW, Levitt AJ (1999) (eds) Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder, Clinical & Academic Publishing, Vancouver, BC, Canada
	A115	Lennon et al., "Azabenzocycloheptenones Part XVIII. Amines and amino-ketones of the tetrahydro-3-benzazepine-1-one series", <i>J. Chem. Soc. Perkin Transacts.</i> (1975) 7:622-626
	A116	Linda D. Williams, <i>Chemistry Demystified</i> 123 (2003)
	A117	Macdonald et al., "Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))-phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): A Potent and selective dopamine D.sub.3 Receptor Antagonist", <i>J. Med. Chem.</i> 46:4952-4964 (2003) American Chemical Society
	A118	Moline et al., (2001) Expert Consensus Guideline Series – Treatment of Depression in Women 2001, March: 112-113
	A119	Müller et al., (2006) <i>Trends in Pharmacological Sciences</i> , 27(9): 455 (Abstract)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A120	National Institute on Drug Abuse, Proceedings of the 41 st Annual Scientific Meeting (1979) pp. 356-401
	A121	Navarro-Vazquez et al., "A study of aryl radical cyclization in enamino esters", J. Org. Chem. 67:3213-20 (2002)
	A122	Niendam et al., "Neurocognitive Performance and Functional Disability in the Psychosis Prodrome", <i>Schizophrenia Research</i> 84:100-111 (2006)
	A123	Orioto et al., "Benzolactams—I: Alkylation of 1,2,4,5-tetrahydro-3-methyl-3h-3-benzazepin-2-one with sodium hydride and alkyl halide", <i>Tetrahedron</i> 36:1017-1021 (1980) Pergamon Press Ltd.
	A124	Orito et al. (Hokkaido Daigaku Kogakubu Kenkyu Hokoku (1979), (96), 41-44
	A125	Orito et al., "Total synthesis of pseudo type of protopine alkaloids", <i>Heterocycles</i> 14(1) 1980
	A126	Pauvert et al., "Silver nitrate-promoted ring enlargement of 1-tribromomethyl-1,2-dihydro-and 1-tribromomethyl-1,2,3,4-tetrahydro-isoquinoline derivatives: application to the synthesis of the anti-anginal zalebradine", <i>Tetrahedron Letters</i> 44:4203-4206 (2003) Pergamon Press Ltd.
	A127	Pawan et al., (1971) <i>British Journal of Pharmacology</i> , 41(2): 416P-417P (CAPLUS abstract)
	A128	Pecherer et al., "The Synthesis of Some 7- and 7,8-substituted 2,3,4,5-tetrahydro-1H-3benzazepines", <i>J. Heterocyclic Chemistry</i> 8(5):779-783 (1971)
	A129	Perry et al., "Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men", <i>BMJ</i> (1995) 310:560-564
	A130	Piesla et al., (2001) <i>Schizophrenia Research</i> 49: 95
	A131	Porras et al., (2002) <i>Neuropsychopharmacology</i> 26: 311-324
	A132	Prous Science Integrity entry 156186
	A133	Prous Science Integrity entry 354056
	A134	Rothman R.B., (1995) <i>Journal of Substance Abuse Treatment</i> , 12(6): 449
	A135	Schlademan et al., "Synthesis of oxo- and 1-hydroxy-azobenzocycloalkanes", <i>J. Chem. Soc. Perkin Transacts.</i> (1972) 2:213-215
	A136	Schaffner et al., "Preventing Severe Mental Illnesses – New Prospects and Ethical Challenges", <i>Schizophrenia Research</i> 51:3-15 (2001)
	A137	Smith et al., "Discovery and SAR of New Benzazepines as Potent and Selective 5-HT _{2C} Receptor Agonists for the Treatment of Obesity", <i>Bioorganic & Medicinal Chemistry Letters</i> 15(5):1467-1470 (2005)
	A138	Smith, B. M. et al., "Discovery and Structure – Activity Relationship of (1 <i>R</i>)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1 <i>H</i> -3-benzazepine (Lorcaserin), a Selective Serotonin 5-HT _{2c} Receptor Agonist for the Treatment of Obesity", [retrieved on 12/21/07]. Retrieved from the Internet. <URL: http://pubs.acs.org/journals/jmcmar/index.html >.
	A139	Tietz et al., "Efficient synthesis of 2, 3, 4, 5-tetrahydro-1 <i>H</i> -3-benzazepines by intramolecular Heck reaction", <i>Synthesis</i> (1993) 9:876-880

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20750-043US1	Application No. 10/561,071
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Brian Smith, et al.	
		Filing Date May 26, 2006	Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	A140	Tietze et al., "Efficient synthesis of 2,3,4,5-tetrahydro-1H-3-benzazepines by intramolecular heck reaction", Institut für Organische Chemie der Universität Göttingen, Tammannstraße 2, D-3400 Göttingen, Germany, received January 29, 1993.
	A141	Tsuang et al., "Towards the Prevention of Schizophrenia", <i>Biol. Psychiatry</i> 48:349-356 (2000)
	A142	Vink et al., "Risk Factors for Anxiety and Depression in the Elderly: A Review", <i>J. Affect. Disord.</i> , doi:10.1016/j.jad.2007.06.005, 16 pages (2007)
	A143	Wise, R.A., (2000) <i>Neuron</i> , 26: 27-33
	A144	Wisner et al., (2002) <i>N. Engl. J. Med.</i> , 347(3): 194-199
	A145	Yoshinaga et al., "Prevention of Mildly Overweight Children from Development of More Overweight Condition", <i>Preventive Medicine</i> 38:172-174 (2004)
	A146	International Search Report dated November 22, 2004 for International Application No. PCT/US04/019670.

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	